Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

OncoBeta ® GmbH, a medical device company specialising in innovative epidermal radioisotope therapies, has announced 12-months interim results from its international Phase IV, multi-centre ...

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Given the rising incidence of colorectal cancer — particularly among younger adults — and ongoing threats to preventive screening in the U.S., the need for timely, optimized CRC screening is greater ...

Exact Sciences delivered a quarter characterized by strong year-over-year revenue growth and margin improvement, but the ...

Black communities often experience systemic barriers to care, leading to disparities in colorectal cancer outcomes, according ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

Q2 2025 Earnings Call Transcript August 6, 2025 Exact Sciences Corporation beats earnings expectations. Reported EPS is $0.22, expectations were $-0.02. Operator: Thank you for standing by. My name is ...

The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...

Brisbane, California Friday, August 8, 2025, 10:00 Hrs [IST] ...

Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...

Exact Sciences beat Q2 expectations, raised its 2025 forecast, and secured U.S. rights to Freenome's CRC blood tests in a ...